However, a recent study performed on CBF-AML patients demonstrated that RAS-mutated cases demonstrated shorter overall survival rates (HR: 1.520; p = 0.04) compared with wild-type RAS [87]. Here, CEBPZ is linked to acute myeloid leukemia.